Amgen

• 

  Top 30 401(k) Plans of 2012

  By Ron Pechtimaldjian, AdvisorOne  |  December 12, 2012

  Brightscope, which provides retirement plan ratings and investment research, released its fourth annual Top 30 401(k) plans with more than $1 billion in assets.

• 

  Obamacare Here to Stay Even With GOP Victory, Analysts Say

  By Gil Weinreich, AdvisorOne  |  October 26, 2012

  Regardless of which party claims the greatest victory in November elections, Obamacare is likely to remain in place while the outcome of budget sequestration will be the key catalyst for the entire sector, Morningstar analysts say.

• Core Competency

  August 23, 2012

  Solid growth and promising research and development pipelines bode well for companies that sell pharmaceutical and related health-care products.

• 

  The Measured Approach to Value

  By Gerald Burstyn  |  March 26, 2012

  Tevye the milkman. He’s not the first person who comes to mind for the average value investor, but according to value guru Vitaliy Katsenelson, we can learn a lot from Tevye.

• High Hopes and Altered Genes

  By Kenneth Silber, Research  |  October 1, 2009

  Biotech has long been a high-risk, high-reward industry. It is an industry in which numerous firms, including many small-caps and start-ups, intensively research possible...

• Alger Tells China Story, Closes Some Funds

  By Janet Levaux, AdvisorOne  |  September 1, 2007

  While recalls on some goods made in China have been grabbing headlines, certain mutual funds that focus on China remain untainted by the scandals. The...

• VC the Hard Way

  By James Picerno  |  November 1, 2006

  "I spend 90 percent of my time on 5 percent of my clients' portfolios," says Dale Stevens, president of Grasswood Partners Inc., a Malibu, Calif....

• HOLDRs Vs. ETFs: What Investors Should Know

  By Staff Writer  |  August 18, 2005

  The rising popularity of exchange-traded funds (ETFs) has opened the door to other new investment products offered as alternatives to mutual funds. Among these are...

• Biotech Funds: Looking for a Cure in 2003

  By Staff Writer  |  February 10, 2003

  Jan. 31, 2003 -- By any measure, biotech stocks suffered a disastrous year in 2002. Mutual funds investing in biotech tracked by Standard & Poor's...

• What's Up, Doc?

  By Staff Writer  |  December 1, 2000

  Faraz Naqvi, Manager and M.D., uses his varied exp